These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31217190)

  • 1. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.
    Mazepa MA; Masias C; Chaturvedi S
    Blood; 2019 Aug; 134(5):415-420. PubMed ID: 31217190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
    Dane K; Chaturvedi S
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use.
    Cataland SR; Wu HM
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S223-9. PubMed ID: 26149028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience with caplacizumab in the management of acute TTP.
    Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
    Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod A; Veyradier A; Coppo P
    J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
    Mazepa MA; Park YA; Raval JS
    Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
    Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
    Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.
    Coppo P;
    Transfus Apher Sci; 2017 Feb; 56(1):52-56. PubMed ID: 28110841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Eur J Haematol; 2018 Oct; 101(4):425-434. PubMed ID: 29889319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.
    Hrdinová J; D'Angelo S; Graça NAG; Ercig B; Vanhoorelbeke K; Veyradier A; Voorberg J; Coppo P
    Haematologica; 2018 Jul; 103(7):1099-1109. PubMed ID: 29674502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Semin Hematol; 2011 Oct; 48(4):242-50. PubMed ID: 22000089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents.
    Gómez-De León A; Villela-Martínez LM; Yáñez-Reyes JM; Gómez-Almaguer D
    Expert Rev Hematol; 2020 May; 13(5):461-470. PubMed ID: 32243196
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.